Comparative Trials For Contraceptives Recommended By FDA Advisory Panel
Executive Summary
Actively controlled comparative trials should be the new paradigm for registration studies of hormonal contraceptives, FDA's Advisory Committee on Reproductive Health Drugs told the agency Jan. 23
You may also be interested in...
Lybrel Label Details Breakthrough Bleeding; Studies Had High Drop-Out Rate
Wyeth could encounter resistance to uptake of its continuous oral contraceptive Lybrel due to high initial rates of intermenstrual bleeding and spotting
Lybrel Label Details Breakthrough Bleeding; Studies Had High Drop-Out Rate
Wyeth could encounter resistance to uptake of its continuous oral contraceptive Lybrel due to high initial rates of intermenstrual bleeding and spotting
Patient-Reported Outcomes Guidance Needs Flexibility, Industry Tells FDA
FDA's draft guidance on patient-reported outcomes (PROs) should offer both greater flexibility and detail, industry commenters told the agency